ophthalmology and therapy

nature machine intelligence

international journal of retina and vitreous

international journal of scientific and engineering research

progress in retinal and eye research

[1] Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration.

[2] Comparison of Drusen Volume Assessed by Two Different OCT Devices

[3] age-related macular degeneration in a randomized controlled trial of low-dose aspirin: rationale and study design of the aspree-amd study

[4] plasma metabolomic study in chinese patients with wet age-related macular degeneration

[5] role of factor h and related proteins in regulating complement activation in the macula, and relevance to age-related macular degeneration

[6] age-related macular degeneration: advances in management and diagnosis

[7] ips cells for modelling and treatment of retinal diseases

[8] multimodality imaging in macular telangiectasia 2: a clue to its pathogenesis

[9] sd-oct morphological changes in wet age-related macular degeneration patients after bevacizumab treatment

[10] association of obesity and age-related macular degeneration in indian population

[11] optical coherence tomography and autofluorescence findings in chronic phototoxic maculopathy secondary to snow-reflected solar radiation

[12] choroidal neovascular membrane

[13] optical coherence tomography angiography

[14] role of protease-inhibitors in ocular diseases

[15] age-related changes in the macula. a histopathological study of fifty indian donor eyes

[16] lifestyle risk factors associated with age-related macular degeneration

[17] kinsenoside ameliorates oxidative stress-induced rpe cell apoptosis and inhibits angiogenesis via erk/p38/nf-κb/vegf signaling

[18] therapeutic antibody-like immunoconjugates against tissue factor with the potential to treat angiogenesis-dependent as well as macrophage-associated human diseases

[19] c-reactive protein as a mediator of complement activation and inflammatory signaling in age-related macular degeneration

[20] Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes.

[21] Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

[22] Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

[23] Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

[24] Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

[25] Interactome Mapping Guided by Tissue-Specific Phosphorylation in Age-Related Macular Degeneration.

[26] Computer-based detection of age-related macular degeneration and glaucoma using retinal images and clinical data

[27] Polarization Variability in Age-related Macular Degeneration.

[28] Relationship between HTRA1 polymorphism and genetic susceptibility of wet age-related macular degeneration in Han population

[29] Influence of mydriasis on optical coherence tomography angiography imaging in patients with age-related macular degeneration.

[30] Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration.

[31] Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

[32] Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?

[33] StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.

[34] Near-Infrared Reflectance Imaging for Quantification of Atrophy associated with Age-related Macular Degeneration.

[35] Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration.

[36] [A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration].

[37] Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?

[38] Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration.

[39] Retinal Spectral Domain Optical Coherence Tomography in Early Atrophic Age-Related Macular Degeneration (AMD) and a New Metric for Objective Evaluation of the Efficacy of Ocular Nutrition

[40] Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration

[41] Retinal-image quality and contrast-sensitivity function in age-related macular degeneration

[42] Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration

[43] Simple Estimation of Clinically Relevant Lesion Volumes Using Spectral Domain–Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration

[44] Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration

[45] Contrast Sensitivity Evaluation in Eyes Predisposed to Age-Related Macular Degeneration and Presenting Normal Visual Acuity

[46] Contrast sensitivity evaluation in eyes predisposed to age-related macular degeneration and presenting normal visual acuity

[47] Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling

[48] cGAS drives noncanonical-inflammasome activation in age-related macular degeneration

[49] Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

[50] Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

[51] intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade

[52] age-related macular degeneration in a randomized controlled trial of low-dose aspirin: rationale and study design of the aspree-amd study

[53] ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration

[54] plasma metabolomic study in chinese patients with wet age-related macular degeneration

[55] avaliação da perimetria macular em pacientes com degeneração macular relacionada à idade por meio do oftalmoscópio de rastreamento a laser evaluation of macular perimetry in patients with age-related macular degeneration using the scanning laser ophthalmoscope

[56] clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

[57] role of factor h and related proteins in regulating complement activation in the macula, and relevance to age-related macular degeneration

[58] age-related macular degeneration: advances in management and diagnosis

[59] association of cfi p.gly119arg gene polymorphism with age-related macular degeneration (amd) disease in the population living in tehran

[60] sd-oct morphological changes in wet age-related macular degeneration patients after bevacizumab treatment

[61] long-lasting effects of anti-vegf/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review

[62] role of the choroid in age-related macular degeneration: a current review

[63] association of obesity and age-related macular degeneration in indian population

[64] successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

[65] treatment of retinal pigment epithelial detachment secondary to exudative age-related macular degeneration

[66] progress and perspectives on the role of rpe cell inflammatory responses in the development of age-related macular degeneration

[67] european survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the age-related eye disease study

[68] choice of cell source in cell-based therapies for retinal damage due to age-related macular degeneration: a review

[69] new approaches in the management of choroidal neovascular membrane in age-related macular degeneration.

[70] prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration

[71] efficacy of vitrectomy and epiretinal membrane peeling in eyes with dry age-related macular degeneration

[72] lifestyle risk factors associated with age-related macular degeneration

[73] automatic screening and grading of age-related macular degeneration from texture analysis of fundus images

[74] long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections

[75] blockade of tumor necrosis factor-alpha: a role for adalimumab in neovascular age-related macular degeneration refractory to anti-angiogenesis therapy

[76] oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration

[77] melatonin in retinal physiology and pathology: the case of age-related macular degeneration

[78] preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis

[79] visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

[80] c-reactive protein as a mediator of complement activation and inflammatory signaling in age-related macular degeneration

[81] Outcomes in the Treatment of Subretinal Macular Hemorrhage Secondary to Age-Related Macular Degeneration: A Systematic Review.